Cargando…
A therapeutic cancer vaccine against GL261 murine glioma
BACKGROUND: Glioblastoma (GBM) is the deadliest of brain tumors. Standard treatment for GBM is surgery, followed by combined radiation therapy and chemotherapy. Current therapy prolongs survival but does not offer a cure. We report on a novel immunotherapy against GBM, tested in an animal model of C...
Autores principales: | Kindy, Mark S., Yu, Jin, Zhu, Hong, Smith, Michael T., Gattoni-Celli, Sebastiano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700644/ https://www.ncbi.nlm.nih.gov/pubmed/26727970 http://dx.doi.org/10.1186/s12967-015-0757-9 |
Ejemplares similares
-
Semi-allogeneic vaccine for T-cell lymphoma
por: Yu, Jin, et al.
Publicado: (2007) -
Semi-allogeneic vaccines and tumor-induced immune tolerance
por: Yu, Jin, et al.
Publicado: (2009) -
Anthracycline-induced cytotoxicity in the GL261 glioma model system
por: Tavener, Amber M., et al.
Publicado: (2021) -
Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model
por: McKelvey, Kelly J., et al.
Publicado: (2020) -
Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells
por: Clark, Aaron J, et al.
Publicado: (2014)